$139.00 – $7,777.00
Indications for Venclesta
– chronic lymphocytic leukemia (CLL):
– Venclexta in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated CLL;
– Venclexta in combination with rituximab is indicated for the treatment of adult patients with CLL with at least one prior line of therapy;
– Venclexta is indicated as monotherapy for the treatment of CLL with 17p deletion or TP53 mutation in adult patients for whom treatment with B-cell receptor signaling pathway inhibitors is not suitable or has not shown the expected result;
– Venclexta is indicated as monotherapy for the treatment of CLL without 17p deletion or TP53 mutation in adult patients who have not responded to chemoimmunotherapy and treatment with B-cell receptor signaling pathway inhibitors;
– acute myeloid leukemia (AML):
Venclexta, in combination with azacitidine or decitabine or low-dose cytarabine, is indicated for the treatment of patients newly diagnosed with AML who are not candidates for intensive induction chemotherapy due to comorbidities or advanced age.
Active ingredient: venetolax
Prescription medicine
| Дозировка | 10 Mg, 50 Mg, 100 Mg |
|---|
